CLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)
Huntington S, Jawaid D, Marx S, Puckett J, Manzoor B, Li S, Emechebe N, Sachin-Bahl S, Ravelo A, Budlong H, Doshi J. CLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345-s346. DOI: 10.1016/s2152-2650(24)01265-5.Peer-Reviewed Original Research